Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer
Abstract Background Surgery is an important component in the treatment of esophageal cancer. For patients not eligible for R0 resection, defined as locally advanced unresectable esophageal cancer, a new approach is to transform the cancer into a resectable state by preoperative treatment. However, p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14054 |
| _version_ | 1818434012372271104 |
|---|---|
| author | Mengying Fan Liang Dai Wanpu Yan Yongbo Yang Yao Lin Keneng Chen |
| author_facet | Mengying Fan Liang Dai Wanpu Yan Yongbo Yang Yao Lin Keneng Chen |
| author_sort | Mengying Fan |
| collection | DOAJ |
| description | Abstract Background Surgery is an important component in the treatment of esophageal cancer. For patients not eligible for R0 resection, defined as locally advanced unresectable esophageal cancer, a new approach is to transform the cancer into a resectable state by preoperative treatment. However, preoperative chemo/radiation is unsatisfactory. Therefore, the aim of this study was to assess the safety and efficacy of chemo/radiotherapy combined with a programmed cell death protein 1 (PD‐1) inhibitor in the preoperative transformation of unresectable esophageal cancer. Methods Patients were evaluated as having unresectable, locally advanced esophageal cancer at baseline and were re‐evaluated as possible R0 resection candidates after PD‐1 inhibitor treatment. Patient data were derived from the prospective database of Peking University Cancer Hospital Thoracic Surgery I. Preoperative chemotherapy plus PD‐1 inhibitor treatment was defined as “transformation treatment.” The objective response rate, operation rate (proportion of patients who underwent surgery), R0 rate, and treatment safety were analyzed retrospectively. Results A total of 36 patients were enrolled into the study, and 94.4% (34/36) completed the planned transformation treatment. The objective response rate was 71.4% (25/35), and 75% (27/36) of the patients who completed transformation treatment underwent surgery. For these surgical patients, 81.5% (22/27) obtained R0 resection, and 22.2% (6/22) had pathological complete response (pCR). During transformation treatment, 22.2% (8/36) patients had ≥ grade 3 complications. There were no reoperations or perioperative deaths. After surgery, 29.6% (8/27) had ≥ grade 3 complications. Conclusions Esophagectomy after immunotherapy is safe with acceptable complications. Compared with chemotherapy alone, chemotherapy combined with immunotherapy had a more favorable transformation effect for patients with unresectable esophageal cancer. |
| first_indexed | 2024-12-14T16:30:13Z |
| format | Article |
| id | doaj.art-2a7e5891611f45edbded3a3206f7cc40 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-14T16:30:13Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-2a7e5891611f45edbded3a3206f7cc402022-12-21T22:54:36ZengWileyThoracic Cancer1759-77061759-77142021-08-0112152182218810.1111/1759-7714.14054Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancerMengying Fan0Liang Dai1Wanpu Yan2Yongbo Yang3Yao Lin4Keneng Chen5The First Department of Thoracic Surgery Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing ChinaThe First Department of Thoracic Surgery Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing ChinaThe First Department of Thoracic Surgery Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing ChinaThe First Department of Thoracic Surgery Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing ChinaThe First Department of Thoracic Surgery Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing ChinaThe First Department of Thoracic Surgery Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing ChinaAbstract Background Surgery is an important component in the treatment of esophageal cancer. For patients not eligible for R0 resection, defined as locally advanced unresectable esophageal cancer, a new approach is to transform the cancer into a resectable state by preoperative treatment. However, preoperative chemo/radiation is unsatisfactory. Therefore, the aim of this study was to assess the safety and efficacy of chemo/radiotherapy combined with a programmed cell death protein 1 (PD‐1) inhibitor in the preoperative transformation of unresectable esophageal cancer. Methods Patients were evaluated as having unresectable, locally advanced esophageal cancer at baseline and were re‐evaluated as possible R0 resection candidates after PD‐1 inhibitor treatment. Patient data were derived from the prospective database of Peking University Cancer Hospital Thoracic Surgery I. Preoperative chemotherapy plus PD‐1 inhibitor treatment was defined as “transformation treatment.” The objective response rate, operation rate (proportion of patients who underwent surgery), R0 rate, and treatment safety were analyzed retrospectively. Results A total of 36 patients were enrolled into the study, and 94.4% (34/36) completed the planned transformation treatment. The objective response rate was 71.4% (25/35), and 75% (27/36) of the patients who completed transformation treatment underwent surgery. For these surgical patients, 81.5% (22/27) obtained R0 resection, and 22.2% (6/22) had pathological complete response (pCR). During transformation treatment, 22.2% (8/36) patients had ≥ grade 3 complications. There were no reoperations or perioperative deaths. After surgery, 29.6% (8/27) had ≥ grade 3 complications. Conclusions Esophagectomy after immunotherapy is safe with acceptable complications. Compared with chemotherapy alone, chemotherapy combined with immunotherapy had a more favorable transformation effect for patients with unresectable esophageal cancer.https://doi.org/10.1111/1759-7714.14054immunotherapyPD‐1 inhibitor treatmentunresectable esophageal cancer |
| spellingShingle | Mengying Fan Liang Dai Wanpu Yan Yongbo Yang Yao Lin Keneng Chen Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer Thoracic Cancer immunotherapy PD‐1 inhibitor treatment unresectable esophageal cancer |
| title | Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer |
| title_full | Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer |
| title_fullStr | Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer |
| title_full_unstemmed | Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer |
| title_short | Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer |
| title_sort | efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer |
| topic | immunotherapy PD‐1 inhibitor treatment unresectable esophageal cancer |
| url | https://doi.org/10.1111/1759-7714.14054 |
| work_keys_str_mv | AT mengyingfan efficacyofprogrammedcelldeathprotein1inhibitorinresectiontransformationtreatmentofesophagealcancer AT liangdai efficacyofprogrammedcelldeathprotein1inhibitorinresectiontransformationtreatmentofesophagealcancer AT wanpuyan efficacyofprogrammedcelldeathprotein1inhibitorinresectiontransformationtreatmentofesophagealcancer AT yongboyang efficacyofprogrammedcelldeathprotein1inhibitorinresectiontransformationtreatmentofesophagealcancer AT yaolin efficacyofprogrammedcelldeathprotein1inhibitorinresectiontransformationtreatmentofesophagealcancer AT kenengchen efficacyofprogrammedcelldeathprotein1inhibitorinresectiontransformationtreatmentofesophagealcancer |